Nachrichten zur Puma Biotechnology Aktie

Image source: The Motley Fool.DATEThursday, May 7, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer, President and Chairman — Alan…

Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.…

…

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support…

Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.…

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026…

Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.…

Long term investing is the way to go, but that doesnt mean you should hold every stock forever. We really…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Investors need to pay close attention to PBYI stock based on the movements in the options market lately.…

Sales of PBYIs sole-marketed drug, Nerlynx, exceeded managements expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.…

Sales of PBYIs sole-marketed drug, Nerlynx exceeded managements expectations in the third quarter. Also, the acquisition of alisertib holds promise.…

Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.…

…

…

…

…

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.…

Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity are part of the Zacks Screen of the Week article.…

Here are four top-performing liquid stocks, Abercrombie & Fitch (ANF), Puma Biotechnology (PBYI), Spotify (SPOT) and Oddity Tech (ODD), which…

Sales of Puma Biotechnologys (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target…

Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.…

…

…

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.…

…

On Puma Biotechnologys (PBYI) first-quarter 2024 earnings call, investors focus is likely to be on the sales performance of its…

…

…

Puma Biotechnologys (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.…

On Puma Biotechnologys (PBYI) fourth-quarter 2023 earnings call, investors focus is likely to be on the sales performance of its…